Ongoing safety review of sibutramine, marketed as Reductil, to make public within this week

The Korea Food and Drug Administration has reviewed additional data that indicate an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using sibutramine, marketed as the weight loss medication Reductil.

Sibutramine is a centrally acting stimulant chemically related to amphetamines. Sibutramine is classified as a Schedule IV controlled substance i...